Vor Biopharma Inc. (VOR): Capital Expenditures
$941.0K
Year ended 2025-12-31
$726.0K
Trailing 12 months to 2026-06-30
-51.9%
3-year compound annual growth
-25.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $941.0K | +310.9% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $229.0K | -78.6% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $1.07M | -87.4% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $8.46M | +117.3% | 2024-03-20, From 2022-01-01 |
| 2021-12-31 | $3.89M | -6.4% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $4.16M | n/a | 2022-03-14, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $941.0K | +310.9% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $2.41M | -0.9% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $4.70M | +17.9% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $49.0K | n/a |
| Vericel Corp (VCEL) | 2025-12-31 | $27.16M | -57.5% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $3.85M | -44.2% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $2.96M | -19.2% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $2.47M | +119.6% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $938.0K | -97.2% |
Compare VOR, RGNX, GLUE, CGEM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗